500 related articles for article (PubMed ID: 27043501)
1. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
Naeem A; Badshah SL; Muska M; Ahmad N; Khan K
Molecules; 2016 Mar; 21(4):268. PubMed ID: 27043501
[TBL] [Abstract][Full Text] [Related]
2. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
3. Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.
Millanao AR; Mora AY; Villagra NA; Bucarey SA; Hidalgo AA
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885734
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of quinolone action and resistance.
Aldred KJ; Kerns RJ; Osheroff N
Biochemistry; 2014 Mar; 53(10):1565-74. PubMed ID: 24576155
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.
Hooper DC; Jacoby GA
Cold Spring Harb Perspect Med; 2016 Sep; 6(9):. PubMed ID: 27449972
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
7. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
Aldred KJ; Schwanz HA; Li G; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
ACS Chem Biol; 2013 Dec; 8(12):2660-8. PubMed ID: 24047414
[TBL] [Abstract][Full Text] [Related]
8. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of and resistance to quinolones.
Bearden DT; Danziger LH
Pharmacotherapy; 2001 Oct; 21(10 Pt 2):224S-232S. PubMed ID: 11642689
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of drug resistance: quinolone resistance.
Hooper DC; Jacoby GA
Ann N Y Acad Sci; 2015 Sep; 1354(1):12-31. PubMed ID: 26190223
[TBL] [Abstract][Full Text] [Related]
12. [Investigation of plasmid-mediated quinolone resistance determinants in Enterobacteriaceae: a multicenter study].
Coban AY; Nohut OK; Tanrıverdi Çaycı Y; Bayramoğlu G; Pirinççiler M; Cetinkaya E; Cekiç Cihan C; Bozdoğan B; Durupınar B
Mikrobiyol Bul; 2012 Jul; 46(3):366-74. PubMed ID: 22951649
[TBL] [Abstract][Full Text] [Related]
13. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
Chen CR; Malik M; Snyder M; Drlica K
J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
[TBL] [Abstract][Full Text] [Related]
14. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.
Aldred KJ; McPherson SA; Wang P; Kerns RJ; Graves DE; Turnbough CL; Osheroff N
Biochemistry; 2012 Jan; 51(1):370-81. PubMed ID: 22126453
[TBL] [Abstract][Full Text] [Related]
15. Role of the Water-Metal Ion Bridge in Quinolone Interactions with
Carter HE; Wildman B; Schwanz HA; Kerns RJ; Aldred KJ
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769202
[TBL] [Abstract][Full Text] [Related]
16. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
Kocsis B; Domokos J; Szabo D
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to quinolones.
Jacoby GA
Clin Infect Dis; 2005 Jul; 41 Suppl 2():S120-6. PubMed ID: 15942878
[TBL] [Abstract][Full Text] [Related]
18. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
Gibson EG; Oviatt AA; Cacho M; Neuman KC; Chan PF; Osheroff N
Biochemistry; 2019 Nov; 58(44):4447-4455. PubMed ID: 31617352
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of plasmid-mediated quinolone resistance.
Tran JH; Jacoby GA
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5638-42. PubMed ID: 11943863
[TBL] [Abstract][Full Text] [Related]
20. Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
Charrier C; Salisbury AM; Savage VJ; Duffy T; Moyo E; Chaffer-Malam N; Ooi N; Newman R; Cheung J; Metzger R; McGarry D; Pichowicz M; Sigerson R; Cooper IR; Nelson G; Butler HS; Craighead M; Ratcliffe AJ; Best SA; Stokes NR
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
